口服枸橼酸铁铵溶液在MRCP中的初步临床应用

目的:研究使用枸橼酸铁铵(FAC)溶液作为胃肠道阴性对比剂在改善磁共振胰胆管成像(MRCP)图像质量中的应用价值。方法:对40例受检者分别进行服用FAC前和服用后5、10、15min的MRCP检查,采用厚层SSFSE序列成像,且参数保持一致,观察胃肠道信号的消除情况、图像质量的改善情况及药物的可接受性。结果:口服FAC后胃和十二指肠的对比信噪比均有明显下降,其中胃和十二指肠均表现为服药前与服药后5、10、15min的对比信噪比,均为P<0.001,同时十二指肠服药后10min与服药后15min,P<0.001;服药后5min与服药后15min,P<0.01;MRCP的图像质量由服药前的2.9298±1.2499增至10.8865±0.8137,P<0.001。受检者均可接受该药物,极个别有轻微不适,症状自行消除,均无延迟不良反应。结论:口服FAC溶液能有效且安全的消除MRCP图像中胃肠道的高信号,明显改善图像质量,更清晰显示胰胆管结构及病变部位,有利于临床诊断。     

口服枸橼酸铁铵在梗阻性黄疸MRCP检查中的应用价值评估

目的评价采用枸橼酸铁铵作为胃肠道口服阴性对比剂对提高梗阻性黄疸患者磁共振胰胆管成像(MRCP)检查质量的作用。方法对50例临床怀疑梗阻性黄疸的患者行MRCP检查,将患者随机分为2组:试验组25例患者,在检查前30min时口服枸橼酸铁铵冲剂;对照组25例患者,不服用任何对比剂。观察患者对口服对比剂的耐受性;对所有患者进行冠状位厚层的半傅立叶单次激励快速自旋回波序列(HASTE)和呼吸触发的3D快速自旋回波序列(RT-3D-TSE)扫描。由2位放射科医师单盲阅片,对2组患者MRCP图像的对比效果和图像质量作评估和分级。结果所有患者对枸橼酸铁铵溶液都有很好的耐受性。口服枸橼酸铁铵溶液后所有试验组MRCP图像上的胃肠道高信号都有很大程度的抑制,对比效果和图像质量有明显改善,胆道解剖结构显示的清晰性明显提高。结论口服枸橼酸铁铵溶液作为安全的胃肠道阴性对比剂在梗阻性黄疸患者的MRCP检查中可以有效降低胃肠道高信号所造成的影响及假象,改善胆道系统的显示情况,便于诊断。     

口服枸橼酸铁铵在胰腺及其周围结构磁共振成像中的应用价值

目的：研究枸橼酸铁铵作为胃肠道阳性对比剂在改善胰腺及其周围结构磁共振成像中的应用价值。方法：82例受检者分成对照组和实验组，其中对照组41例直接行MRI检查，而实验组41例口服枸橼酸铁铵溶液300ml后进行MRI检查，均采用SIEMENS！．0T MRI扫描仪，轴位和冠状位常规薄层扫描成像。资深放射科医生对图像进行评估后进行统计学分析。结果：实验组和对照组MRI图像质量有显著性差异（U=410．00，P＜0．0005），实验组明显优于对照组。结论：口服枸橼酸铁铵溶液后胃肠道内的水在T1WI呈高信号，从而增加了胰腺与其周围结构的影像层次和对比度，有利于胰腺和周围结构疾病的正确诊断。     

口服枸橼酸铁铵对MRCP的影响

目的: 探讨口服枸橼酸铁铵前后MRCP的临床应用价值.材料和方法: 对43例可疑胰胆管病变者行常规MRI及口服枸橼酸铁铵前后MRCP,并根据术后病理诊断,对照研究口服枸橼酸铁铵前后MRCP的诊断准确率.结果: 口服对比剂后图像质量明显改善;常规MRI,综合口服对比剂后前后MRCP定位、定性诊断的准确率明显提高,分别达到100%及95.4%.结论: 口服枸橼酸铁铵后能有效抑制胃、十二指肠内液体高信号,明显改善胰胆管的显像效果,综合口服对比剂前后MRCP对胆胰系统病变具有重要的临床应用价值.     

口服枸橼酸铁铵在胆囊管MRCP检查中的应用价值

目的：研究磁共振胰胆管成像显示胆囊管的最佳检查方法,并比较口服枸橼酸铁铵后胆囊管显示率的变化。分析胆囊管的显示在临床中的应用价值。方法：53例行常规MRCP检查者为正常对照组,69例检查前口服枸橼酸铁铵患者为实验组。另27例先常规行MRCP检查,再口服枸橼酸铁铵后做MRCP。在MRCP图像上,多角度、多方位观察胆囊管的显示情况,比较正常对照组与实验组胆囊管的显示率,比较口服枸橼酸铁铵前后胆囊管显示率的变化情况。结果：53例行常规MRCP检查的胆囊管显示率为71．7％（38／53）,69例口服枸橼酸铁铵后胆囊管的显示率为87．0％（60／69）。27例口服枸橼酸铁铵后做自身前后对照的病例中,服药前显示率为70．4％（19／27）,服药后显示率为88．9％（24／27）。在正常对照组与实验组间及口服枸橼酸铁铵前后做MRCP检查的病例中,服药后胆囊管的显示率明显提高,并具有显著统计学意义。结论：检查前口服枸橼酸铁铵在MRCP技术中的应用提高了正常胆囊管的显示,有利于胆囊切除术前常规了解胆囊管的正常解剖及变异,避免术中不必要的胆源性损伤及术后并发症的发生。     

口服枸橼酸铁铵在磁共振胰胆管成像中的价值

目的　研究枸橼酸铁铵作为胃肠道阴性对比剂对改善磁共振胰胆管成像 (MRCP)质量的价值。方法　 6 0例受检者归入本次研究 ,其中 30例受检者口服枸橼酸铁铵溶液 (内含 6 0 0mg枸橼酸铁铵 )后进行MRCP检查 ,30例则直接进行MRCP检查 ,均采用GE 1 5TMR扫描仪 ,冠状面常规薄层成像 ,原始图像经工作站处理 ,采用最大信号强度投影 (MIP)技术获得新图像。资深放射科医生对2组图像进行评估后行统计学分析。结果　采用非参数检验Raddit分析 ,未服用枸橼酸铁铵溶液组Raddit值的均数为 0 2 75 ,服用枸橼酸铁铵组Raddit值的均数为 0 72 5 ,计算U值为 6 0 37,P <0 0 0 1。结论　口服枸橼酸铁铵溶液可完全抑制胃及十二指肠内液体 ,排除其干扰 ,使MRCP更能清楚地显示胰胆管     

腹部磁共振成像应用口服造影剂枸橼酸铁铵的研究

缺乏一种理想的口服造影剂已成为腹部ＭＲＩ发展中的一大障碍。笔者选用枸橼酸铁铵（ＦＡＣ）作为ＭＲ口服造影剂，对其作用机理、增强规律、最佳浓度、造影方法、临床效果等问题进行了试管、动物实验和临床对照研究。ＦＡＣ具有较强的弛豫增强作用，低浓度时，以缩短Ｔ＿１为主，信号强度随浓度升高而增高；高浓度时，以缩短Ｔ＿２为主，信号强度随浓度升高而降低。当ＦＡＣ浓度为２．１ｍｍｏｌ／Ｌ时，Ｔ＿１Ｗ和Ｔ＿２Ｗ像均得到满意的对比增强，故为最佳浓度。ＦＡＣ口服造影可以标记胃肠道、提高邻近正常结构和病灶的解剖分辨率。造影时配合应用胃肠道松弛剂效果更好，低张造影组肝左叶、胰腺各段及胆总管下端的分辨效果明显优于平扫组。ＦＡＣ具有价格低廉、无毒副作用、造影效果良好等优点，是较理想的ＭＲ口服造影剂。     

口服枸橼酸铁铵在胆胰系MRI中的应用价值评价

目的:评价口服枸橼酸铁铵在胆胰系MRI中的应用价值。方法:对86例怀疑有胰胆管系统疾病的患者行口服枸橼酸铁铵前、后MRCP及常规胆胰系MRI,对服用对比剂前后MRCP图像质量、邻近脏器边缘分辨力及各序列上胃十二指肠腔与肝脏的对比噪声比进行自身对照研究,由资深放射科医生对两组图像进行评价,SPSS统计软件进行统计分析。结果:服用对比剂后TrueFISP及HASTE序列均显示胃、十二指肠腔内信号显著降低,形成阴性对比;而FL2D序列胃、十二指肠腔内信号增强,形成阳性对比;胃十二指肠腔内液体造成的背景高信号被完全抑制,单层法与多层法MRCP图像质量及邻近的肝胆胰等结构边缘分辨力均明显提高。结论:口服枸橼酸铁铵能明显提高胆胰系MRI的成像质量,对诊断胆胰系病变具有重要的临床应用价值。     

枸橼酸铁铵泡腾颗粒在上腹部MRI扫描中的初步应用

以往上腹部MRI由于受到呼吸运动等的影响而应用较少,近年来随着MRI硬件与软件技术的发展,MRI越来越多地应用于上腹部疾病的诊断中.但是,由于胃肠道与周围组织信号对比不明显而T2WI胃肠道内水呈高信号影响诊断,特别是,磁共振胰胆管成像（magnetic resonance cholangiopancreatography,MRCP）检查因其采用重T2加权水成像技术对体内流动缓慢或静止的液体成像,所以胃、肠腔内的液体也常同时呈现明显高信号,     

口服枸橼酸铁铵溶液在MR水成像中的应用

目的:探讨口服枸橼酸铁铵溶液(FAC)在水成像中的应用价值。方法:回顾性分析74例口服FAC及20例未口服FAC行水成像检查的病人图像,评价胃肠信号消除情况和胰胆管及泌尿系的显示情况,并对图像质量进行评价。结果:采用Ridit分析,口服FAC组Raidit值的均数为0.94,未口服FAC组Raidit值的均数为0.50,计算u统计量为8.8076,P<0.001。74例口服FAC后MRCP及MRU扫描,胃和十二指肠内的高信号被完全抑制,除2例因腹水影响诊断外,其余病例图像质量均优,能更清晰显示胰胆管及泌尿道的正常及异常情况,对病变的定位、定性诊断率明显提高。相反,20例未口服FAC行水成像检查的病人图像,由于受胃肠内液体的影响,严重影响诊断。结论:FAC可完全抑制胃及十二肠内液体信号,排除干扰,明显提高水成像的图像质量,对诊断胰胆系及泌尿系病变具有重要的临床应用价值。     

口服枸橼酸铁铵泡腾颗粒在MRCP检查中定位胆结石的应用

目的分析口服枸橼酸铁铵泡腾颗粒在磁共振胆胰管成像(MRCP)检查中对影像质量、胆结石检出率的影响及对临床胆结石手术的指导价值。方法共收集2014年10月—12月68例胆道系统结石病变病人资料,均行常规MRCP检查,口服枸橼酸铁铵泡腾颗粒30 min后再行MRCP检查,2位高年资影像诊断医生分别对服药前后影像质量进行评分,用Kappa检验分析评价双盲法MRCP影像质量评分的一致性。以手术结果为金标准,对照口服枸橼酸铁铵泡腾颗粒30 min前后MRCP检查定位胆结石的准确率,采用χ2检验对胆结石检出率进行分析。结果口服枸橼酸铁铵泡腾颗粒30 min后行MRCP检查较服药前MRCP影像评分明显提高,且2位高年资影像诊断医生影像质量评分的一致性良好(P0.05)。服药后对肝管、胆囊、胆总管上段和中段部位的结石的检出率均高于服药前(均P0.05),但胆总管下段结石显示较差(P0.05)。结论口服枸橼酸铁铵泡腾颗粒对胰胆树解剖和病变的显示更清晰,提高影像质量,提高胆道系统结石定位的准确性,对临床手术定位具有重要的指导价值。     

背景抑制全身扩散加权成像口服枸橼酸铁铵泡腾颗粒消除胃肠道干扰的可行性

目的:探讨口服枸橼酸铁铵泡腾颗粒(FAC)对背景抑制全身扩散加权成像(DWIBS)图像质量及其定量参数的影响.方法:2019年9-11月招募15名健康志愿者,年龄23～53岁(38.2±12.5岁),分别于空腹和口服FAC 20 min后行DWIBS扫描.测量并计算b=800、1500、2000 s/mm2图像上胃、十...     

Value of MRCP using oral Gd-DTPA as negative contrast materials in diagnosis of atypical juxtapapillary duodenal diverticulum

ObjectiveTo investigate value of magnetic resonance cholangiopancreatography (MRCP) using oral diluted gadolinium (Gd)-diethylenetriamine penta-acetic acid (DTPA) as negative contrast materials in diagnosis of juxtapapillary duodenal diverticulum with atypical imaging features.MethodsNineteen patients with juxtapapillary duodenal diverticula of which imaging findings were atypical underwent MRCP using oral diluted Gd-DTPA as negative contrast materials after conventional MRCP without any oral contrast materials.ResultsTwenty diverticula were revealed in the 19 patients. At conventional MRCP, the diverticula appeared as rounded lesion with high signal intensity. After oral administration of diluted Gd-DTPA, they disappeared at MRCP. These entities were diagnosed as duodenal diverticula for they communicate with duodenal lumen.ConclusionMRCP using oral Gd-DTPA as negative contrast materials can be helpful in obtaining definitive diagnosis of those juxtapapillary duodenal diverticula without typical imaging features.     

口服超顺磁性氧化铁在MRCP中的应用

目的：研究超顺磁性氧化铁(SPIO)作为胃肠道阴性对比剂在改善磁共根胰胆管成像(MRCP)质量的应用。方法：30例受检者口服2mmol/Fe／1的SPIO液100m1后进行TSE MRCP检查，采用西门子1．5T MRI扫描机，服药前后常规行单层和多层扫描，原始图像经工作站处理后，采用最大信号强度投影技术重建获得新图像。结果：口服SPIO溶液可以完全抑制胃及十二指肠内液体信号，排除其干扰，使MRCP时胰胆管显影更加清晰。结论：口服SPIO，行MRCP检查，能抑制胃肠道内液体信号，使胰胆管显影更加清晰，特别是在TSEMRCP成像时效果更佳。     

New intravascular contrast agent applied to dynamic contrast enhanced MR imaging of human breast cancer

Purpose: 
To evaluate the feasibility of using dynamic contrast-enhanced MR imaging with a new intravascular contrast agent in grading human breast cancer. Material and Methods: 
23 patients with 27 breast tumors (21 carcinomas and 6 fibroadenomas) were examined with dynamic MR imaging after administration of Clariscan, an iron oxide nanoparticle with large T1 relaxivity and a long plasma half life. A 3D T1-weighted gradient echo sequence with an acquisition time of 60 s was repeated at regular intervals of 3-5 min before and up to 1 h after injection of 2 mg/kg b.w. of Clariscan. The endothelial transfer constant, Kps, which reflects overall vascular permeability, and the fractional plasma volume, fPV, were estimated from time-intensity curves acquired from three separate regions of interest (ROIs): whole tumor, a permeability hot spot, and a blood volume hot spot. Kps and fPV were compared to the results of histologic tumor grading (Scarff-Bloom-Richardson, SBR) and microvascular density, MVD. Results: 
A statistically significant correlation between the MR-derived Kps parameters and the SBR score was obtained for the whole tumor ROI (R = 0.70), and for the permeability hot spot ROIs (R = 0.67). A correlation between fPV and SBR was detected for the blood volume hot spot ROIs (R = 0.48). There was no statistically significant correlation between Kps or fPV with MVD. Conclusion: 
The results support the hypothesis that dynamic MR with the intravascular contrast agent Clariscan may be used for non-invasive tumor grading.     

Elimination of bowel fluid artifact on abdominal DWI using oral contrast agent ferric ammonium citrate

The clinical usefulness, as well as the advantages and limitations of DWI in the abdomen and pelvis, currently are under discussion. One of the limitations is the artifact from bowel fluid that may obscure lesion signals or make it difficult to detect them. The purpose of this study was to examine evidence as to whether an oral contrast agent of ferric ammonium citrate could eliminate this artifact from the bowel loop. The study consisted of a phantom study and clinical study. The density of the phantom compounded it to 1-6 times, 8 times and 12 times. We changed the density with ferric ammonium citrate to find the best density. The pulse sequence used SE-PEI and, variable parameter changed TE and b value. The signal intensity of the phantoms was visually analyzed. We took the results to an outside observer as a clinical study and confirmed the effect visually. When a signal of ferric ammonium citrate extended TE time and increased b value, it fell. As it thickened the density of phantom, it was the result that the signal deteriorated, and was good. However, an artifact from ferric ammonium citrate appeared when we exceeded 5x density. The signal of the bowel fluid artifact disappeared by having a normal person take the 4x density as in the clinical study. Elimination of bowel fluid artifact on abdominal DWI was able to suggest the possibility of taking the ferric ammonium citrate solution at 4x density.     

胃肠道阴性对比剂在磁共振胰胆管成像中的应用研究

目的　研究胃肠道阴性对比剂在改善磁共振胰胆管成像 (MRCP)质量的应用。方法　体外实验 :将马根维显 (Gd -DTPA)和欧乃影注射液分别用温开水稀释为不同浓度制剂盛入 10ml注射器内 ,以温开水作空白对照 ,然后行MRCP扫描 ,以获取对比剂最佳稀释倍数。临床实验 :对 3 9例临床疑胰胆管系统疾病申请MRCP检查患者行口服稀释 3 0 0倍马根维显溶液前后常规腹部MR和MRCP检查 ,扫描参数及定位完全相同。结果　体外实验 :稀释 3 0 0倍的马根维显溶液和稀释 2 0 0倍的欧乃影溶液为最佳浓度。临床实验 :所有病例口服稀释 3 0 0倍的马根维显溶液后 ,胃与十二指肠内的液体高信号被明显抑制 ,MRCP胆管显示效果对比在服对比剂前后具有显著性意义 (P <0 .0 5 )。结论　口服稀释 3 0 0倍的马根维显溶液作为胃肠道阴性对比剂可有效地改善MRCP图像的质量。